Expectations concerning cancer treatment: perspectives of medical oncologists and patients on advanced, unresectable lung carcinoma
“Introduction. This study seeks to compare expectations regarding systemic cancer treatment for advanced lung cancer from the perspectives of both patient and medical oncologist. A cross-sectional study involving 17 medical oncologists from 13 Spanish hospitals between 2021 and 2022. Patients with advanced, unresectable lung cancer were recruited prior to initiating systemic cancer treatment.”
First-Line Serplulimab Receives Positive CHMP Opinion for ES-SCLC
“The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of serplulimab (Hansizhuang) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).”
PM2.5 Exposure May Increase Lung Cancer Risk in Women Who Have Never Smoked
“Lung cancer has long been associated with smoking, but recent studies suggest that air pollution, particularly exposure to fine particulate matter (PM2.5), may play a significant role in the development of lung cancer in women who have never smoked. A study presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference highlights this emerging risk, drawing attention to a potential link between PM2.5 exposure and advanced-stage lung cancer diagnoses, especially in women with certain genetic mutations.”
FDA Approves Amivantamab Plus Carboplatin, Pemetrexed For Certain Patients With NSCLC
“The US Food and Drug Administration has approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) plus carboplatin and pemetrexed for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. The approval is for patients whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.”
New Cancer Cachexia Treatment Boosts Weight Gain and Patient Activity
“Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting. The results of the randomized phase 2 clinical trial, which included 187 individuals who experienced cachexia with lung, pancreatic, or colorectal cancer, were reported in the New England Journal of Medicine on Sept. 14, 2024.”
New Mount Sinai Study Reveals Disparities in Lung Cancer Testing
“New York, NY (September 18, 2024) A new Mount Sinai study published in the Journal of the National Cancer Institute on September 10, 2024, has found that people with lung cancer face big differences in getting important tests based on their race and income.”
SLU Researchers Identify Sex-Based Differences in Immune Responses Against Tumors
“Researchers at Saint Louis University School of Medicine investigated differences in T-cell responses between male and female patients with lung cancer that may help direct future treatments. T-cell responses are part of the adaptive immune system, part of the body’s “smart system” that monitors for threats and fights them with customized defenses.”
